These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 29037578)

  • 1. A phase I safety and immunogenicity dose escalation trial of plague vaccine, Flagellin/F1/V, in healthy adult volunteers (DMID 08-0066).
    Frey SE; Lottenbach K; Graham I; Anderson E; Bajwa K; May RC; Mizel SB; Graff A; Belshe RB
    Vaccine; 2017 Dec; 35(48 Pt B):6759-6765. PubMed ID: 29037578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague.
    Williamson ED; Packer PJ; Waters EL; Simpson AJ; Dyer D; Hartings J; Twenhafel N; Pitt ML
    Vaccine; 2011 Jun; 29(29-30):4771-7. PubMed ID: 21570437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis.
    Honko AN; Sriranganathan N; Lees CJ; Mizel SB
    Infect Immun; 2006 Feb; 74(2):1113-20. PubMed ID: 16428759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.
    Gupta G; Khan AA; Rao DN
    Scand J Immunol; 2010 Mar; 71(3):186-98. PubMed ID: 20415784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates.
    Mizel SB; Graff AH; Sriranganathan N; Ervin S; Lees CJ; Lively MO; Hantgan RR; Thomas MJ; Wood J; Bell B
    Clin Vaccine Immunol; 2009 Jan; 16(1):21-8. PubMed ID: 18987167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
    Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
    Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine.
    Huang J; D'Souza AJ; Alarcon JB; Mikszta JA; Ford BM; Ferriter MS; Evans M; Stewart T; Amemiya K; Ulrich RG; Sullivan VJ
    Clin Vaccine Immunol; 2009 May; 16(5):719-25. PubMed ID: 19261773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.
    Yamanaka H; Hoyt T; Yang X; Golden S; Bosio CM; Crist K; Becker T; Maddaloni M; Pascual DW
    Infect Immun; 2008 Oct; 76(10):4564-73. PubMed ID: 18694965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.
    Williamson ED; Stagg AJ; Eley SM; Taylor R; Green M; Jones SM; Titball RW
    Vaccine; 2007 Jan; 25(6):1142-8. PubMed ID: 17101198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.
    Amemiya K; Meyers JL; Rogers TE; Fast RL; Bassett AD; Worsham PL; Powell BS; Norris SL; Krieg AM; Adamovicz JJ
    Vaccine; 2009 Apr; 27(16):2220-9. PubMed ID: 19428836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles.
    Sabhnani L; Manocha M; Sridevi K; Shashikiran D; Rayanade R; Rao DN
    FEMS Immunol Med Microbiol; 2003 Oct; 38(3):215-29. PubMed ID: 14522457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative anti-F1 and anti-V IgG ELISAs as serological correlates of protection against plague in female Swiss Webster mice.
    Little SF; Webster WM; Wilhelm H; Fisher D; Norris SL; Powell BS; Enama J; Adamovicz JJ
    Vaccine; 2010 Jan; 28(4):934-9. PubMed ID: 19925906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts.
    Arlen PA; Singleton M; Adamovicz JJ; Ding Y; Davoodi-Semiromi A; Daniell H
    Infect Immun; 2008 Aug; 76(8):3640-50. PubMed ID: 18505806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A safety and immunogenicity study of a novel subunit plague vaccine in cynomolgus macaques.
    Liu L; Wei D; Qu Z; Sun L; Miao Y; Yang Y; Lu J; Du W; Wang B; Li B
    J Appl Toxicol; 2018 Mar; 38(3):408-417. PubMed ID: 29134676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
    Eyles JE; Butcher WA; Titball RW; Hill J
    Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One year immunogenicity and safety of subunit plague vaccine in Chinese healthy adults: An extended open-label study.
    Hu J; Jiao L; Hu Y; Chu K; Li J; Zhu F; Li T; Wu Z; Wei D; Meng F; Wang B
    Hum Vaccin Immunother; 2018; 14(11):2701-2705. PubMed ID: 29927704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of subunit plague vaccine: A randomized phase 2a clinical trial.
    Chu K; Hu J; Meng F; Li J; Luo L; Xu J; Yuan Z; Li Z; Chen W; Jiao L; Chang Y; Wang B; Hu Y
    Hum Vaccin Immunother; 2016 Sep; 12(9):2334-40. PubMed ID: 27159397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.
    Leary SE; Griffin KF; Garmory HS; Williamson ED; Titball RW
    Microb Pathog; 1997 Sep; 23(3):167-79. PubMed ID: 9281474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.
    Anderson GW; Leary SE; Williamson ED; Titball RW; Welkos SL; Worsham PL; Friedlander AM
    Infect Immun; 1996 Nov; 64(11):4580-5. PubMed ID: 8890210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice.
    Uppada SB; Bhat AA; Sah A; Donthamshetty RN
    Vaccine; 2011 Nov; 29(50):9352-60. PubMed ID: 22001881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.